Ischemic heart disease and ankylosing spondylitis—assessing the role of inflammation

被引:0
|
作者
Michal Vinker Shuster
Omer Gendelman
Shmuel Tiosano
Doron Comaneshter
Arnon D. Cohen
Howard Amital
机构
[1] The Hebrew University of Jerusalem,Department of Medicine ‘B’, Zabludowicz Center for Autoimmune Diseases
[2] Hadassah Hebrew University Medical Center,Sackler Faculty of Medicine
[3] Sheba Medical Center,Chief Physician’s Office
[4] Tel-Aviv University,Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences
[5] Clalit Health Services,undefined
[6] Ben-Gurion University of the Negev,undefined
来源
Clinical Rheumatology | 2018年 / 37卷
关键词
Ankylosing spondylitis; Autoimmunity; Ischemic heart disease; Risk factors;
D O I
暂无
中图分类号
学科分类号
摘要
To assess the association of ankylosing spondylitis (AS) and ischemic heart disease (IHD) compared to traditional cardiovascular (CV) risk factors. Primary care and hospital records of patients with AS were analyzed, using the largest health maintenance organization in Israel, the “Clalit” Health Services data. These patients were compared with age- and gender-matched controls regarding the proportion of IHD in a cross-sectional study. Parameters including socioeconomic status, body mass index (BMI), smoking habits, and coexistent medical conditions hypertension, hyperlipidemia, and diabetes mellitus (DM) - as well as the use of NSAIDs and anti-TNFs were also assessed. The study included 4076 AS patients compared to 20,290 age- and gender-matched controls without AS. The proportion of IHD was higher among AS patients as compared to controls (14.1 vs. 6.36%, respectively, p < 0.01) and patients treated with anti-TNFs had a lower risk for IHD compared to non-anti-TNF users. The proportion of hypertension, hyperlipidemia, DM, and smoking was also higher among AS patients. However, in multivariate analyses following adjustment to these risk factors, AS was not found to be associated with IHD nor anti-TNF therapy to be a protective factor. Patients with AS have more traditional CV risk factors, thus are in a higher risk for IHD. AS itself was not shown to be independently associated with IHD. These findings emphasize the multifactorial process leading to increased proportion of IHD among AS patients and the need for a stringent control of traditional risk factors in these patients.
引用
收藏
页码:1053 / 1058
页数:5
相关论文
共 50 条
  • [41] Serum amyloid A – an indicator of inflammation in ankylosing spondylitis
    U. Lange
    B. Boss
    J. Teichmann
    H. U. Klör
    G. Neeck
    Rheumatology International, 2000, 19 : 119 - 122
  • [42] Are inflammation and ossification on separate tracks in ankylosing spondylitis?
    Claudepierre, Pascal
    Wendling, Daniel
    JOINT BONE SPINE, 2008, 75 (05) : 520 - 522
  • [43] Immunohistologic examinations of sacroiliac inflammation in ankylosing spondylitis (AS)
    Braun, J
    Neure, L
    Francois, R
    Bywaters, E
    Sieper, J
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S112 - S112
  • [44] The role of fibrinogen to albumin ratio in ankylosing spondylitis: Correlation with disease activity
    Liu, Meng
    Huang, Yukai
    Huang, Zhengping
    Zhong, Zheng
    Deng, Weiming
    Huang, Zhixiang
    Huang, Qidang
    Li, Tianwang
    CLINICA CHIMICA ACTA, 2020, 505 : 136 - 140
  • [45] 'All disease begins in the gut'-the role of the intestinal microbiome in ankylosing spondylitis
    Harkins, Patricia
    Burke, Eoghan
    Swales, Catherine
    Silman, Alan
    RHEUMATOLOGY ADVANCES IN PRACTICE, 2021, 5 (03)
  • [46] Role of the physical examination of the spine in the assessment of disease activity in ankylosing spondylitis
    Song, I.
    Haibel, H.
    Hilgert, E.
    Sieper, J.
    Rudwaleit, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 63 - 64
  • [47] EPITRANSCRIPTOMIC CONTROL OF INFLAMMATION IN ISCHEMIC HEART DISEASE
    Gatsiou, A.
    Tual-Chalot, S.
    Bonini, F.
    Cesarini, V.
    Martini, M.
    Ortega-Gomez, A.
    Ramadurai, D. K. A.
    Hoffmann, J.
    Regen, T.
    Shook, K.
    Chen, W.
    Guenther, S.
    Silvestris, D. A.
    Kwak, S.
    Selzman, C. H.
    Spyridopoulos, I.
    Braun, T.
    Waisman, A.
    Dimmeler, S.
    Gallo, A.
    Drakos, S.
    Soehnlein, O.
    Stellos, K.
    CARDIOVASCULAR DRUGS AND THERAPY, 2020, 34 (02) : 287 - 288
  • [48] Molecular Imaging of Inflammation in Ischemic Heart Disease
    Bakerman I.
    Wardak M.
    Nguyen P.K.
    Current Cardiovascular Imaging Reports, 2018, 11 (6)
  • [49] ROLE OF LEUKOCYTE SUBSETS IN THE INFLAMMATION, OXIDATIVE STRESS AND BONE TURNOVER IN ANKYLOSING SPONDYLITIS PATIENTS
    Jimenez-Gomez, Y.
    Lopez-Pedrera, C.
    Font, P.
    Ruiz-Limon, P.
    Perez-Sanchez, C.
    Barbarroja, N.
    Castro-Villegas, M. D. C.
    Calvo, J.
    Abalos-Aguilera, M. D. C.
    Escudero-Contreras, A.
    Collantes-Estevez, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 493 - 493
  • [50] Investigation of the role of ANKH in ankylosing spondylitis
    Timms, AE
    Zhang, Y
    Bradbury, L
    Wordsworth, BP
    Brown, MA
    ARTHRITIS AND RHEUMATISM, 2003, 48 (10): : 2898 - 2902